title: Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.
abstract: BACKGROUND
  During clinical development of the licensed Japanese encephalitis chimeric virus vaccine (JE-CV), the neutralization capacity of vaccine-induced antibodies was assessed against the vaccine virus and against well characterized wild-type (wt) viruses isolated between 1949-1991. We assessed whether JE-CV-induced antibodies can also neutralize more recent wt Japanese encephalitis virus (JEV) isolates including a genotype 1 isolate.
  
  
  METHODS
  Sera from 12-18 month-old children who received a single dose of JE-CV in a phase III study in Thailand and the Philippines (ClinicalTrials.gov NCT00735644) were randomly selected and pooled according to neutralization titer against JE-CV into eight samples. Neutralization was assessed by plaque reduction neutralization tests (PRNT50) against three recent isolates from JEV genotypes 1 and 3 in addition to four JEV previously tested.
  
  
  RESULTS
  Neutralization titers against the three recent JEV strains were comparable to those observed previously against other strains and the vaccine virus. The observed differences between responses to genotype 1 and 3 viruses were within assay variability for the PRNT50.
  
  
  CONCLUSIONS
  The results were consistent with previously generated data on the neutralization of wt JEV isolates, immune responses induced by JE-CV neutralize recently isolated virus from southeast (SE) Asia and India.
authors.forename: Matthew
authors.initials: M
authors.lastname: Bonaparte
authors.forename: Bashir
authors.initials: B
authors.lastname: Dweik
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Feroldi
authors.forename: Claude
authors.initials: C
authors.lastname: Meric
authors.forename: Alain
authors.initials: A
authors.lastname: Bouckenooghe
authors.forename: Stephen
authors.initials: S
authors.lastname: Hildreth
authors.forename: Branda
authors.initials: B
authors.lastname: Hu
authors.forename: Sutee
authors.initials: S
authors.lastname: Yoksan
authors.affiliation: Sanofi Pasteur Global Clinical Immunology Department, Swiftwater, USA. mark.boaz@sanofipasteur.com.
authors.forename: Mark
authors.initials: M
authors.lastname: Boaz
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D001210:Asia, Southeastern; D015331:Cohort Studies; D004664:Encephalitis Virus, Japanese / Q000235:genetics / Q000276:immunology*; D004672:Encephalitis, Japanese / Q000097:blood / Q000821:virology*; D005838:Genotype; D006801:Humans; D007194:India; D007223:Infant; D022321:Japanese Encephalitis Vaccines / Q000008:administration & dosage / Q000276:immunology*; D009500:Neutralization Tests; D013552:Swine
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D022321:Japanese Encephalitis Vaccines